Type of antimicrobial drugs representing more than one percent of antimicrobial drugs given to treat community-onset and HAIs*
| Type | Total | Community-onset infections† | Healthcare-associated infections |
| Total antimicrobial drugs | 163 (100.0) | 93 (100.0) | 70 (100.0) |
| Ceftriaxone | 25 (15.3) | 19 (20.4) | 6 (8.6) |
| Piperacillin–tazobactam | 22 (13.5) | 10 (10.8) | 12 (17.1) |
| Cefmetazole | 13 (8.0) | 11 (11.8) | 2 (2.9) |
| Cefazolin | 12 (7.4) | 4 (4.3) | 8 (11.4) |
| Ampicillin–sulbactam | 12 (7.4) | 7 (7.5) | 5 (7.1) |
| Meropenem | 9 (5.5) | 3 (3.2) | 6 (8.6) |
| Vancomycin (parenteral)‡ | 8 (4.9) | 0 (0.0) | 8 (11.4) |
| Levofloxacin | 6 (3.7) | 4 (4.3) | 2 (2.9) |
| Cefozopran | 6 (3.7) | 2 (2.2) | 4 (5.7) |
| Ampicillin | 5 (3.1) | 5 (5.4) | 0 (0.0) |
| Cefoperazone–sulbactam | 4 (2.5) | 4 (4.3) | 0 (0.0) |
| Ceftazidime | 3 (1.8) | 1 (1.1) | 2 (2.9) |
| Trimethoprim–sulfamethoxazole | 3 (1.8) | 2 (2.2) | 1 (1.4) |
| Amoxicillin | 2 (1.2) | 2 (2.2) | 0 (0.0) |
| Amoxicillin–clavulanate | 2 (1.2) | 1 (1.1) | 1 (1.4) |
| Piperacillin | 2 (1.2) | 2 (2.2) | 0 (0.0) |
| Cefcapene | 2 (1.2) | 2 (2.2) | 0 (0.0) |
| Minocycline | 2 (1.2) | 0 (0.0) | 2 (2.9) |
| Rifampicin | 2 (1.2) | 2 (2.2) | 0 (0.0) |
| Micafungin | 2 (1.2) | 0 (0.0) | 2 (2.9) |
*Values are the number of antimicrobial drugs, with the percentage of the total number of antimicrobial drugs in parenthesis according to the type of infections.
†Community-onset infections were defined as infections for which signs and symptoms began in community settings, including nursing facilities and rehabilitation facilities. However, community-onset infections that met the definition of healthcare-associated infections were excluded.
‡Parenteral formulation of the drug.